Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study

2021 ◽  
Author(s):  
Corina Behrenbruch ◽  
Sowmya Prabhakaran ◽  
Dilshan Udayasiri ◽  
Frédéric Hollande ◽  
Michael Michael ◽  
...  
Keyword(s):  
Cohort Study ◽  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Survival Benefit ◽  
Colorectal Liver Metastases ◽  
Surgery First

The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score

2020 ◽  
Vol 26 (1) ◽  
pp. 126-134
Author(s):  
Yoshihiko Yonekawa ◽  
Kay Uehara ◽  
Takashi Mizuno ◽  
Toshisada Aiba ◽  
Atsushi Ogura ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Survival Benefit ◽  
Colorectal Liver Metastases ◽  
Tumor Burden ◽  
High Tumor Burden

scholarly journals Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14523-e14523 ◽  
Author(s):  
Jianmin Xu ◽  
Dexiang Zhu ◽  
Yunshi Zhong
Keyword(s):  
High Risk ◽  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Median Survival ◽  
Survival Data ◽  
Survival Benefit ◽  
Colorectal Liver Metastases ◽  
Risk Group ◽  
Low Risk ◽  
Significant Difference

e14523 Background: Whether patients with resectable colorectal liver metastases (CRLM) receive a survival benefit from neoadjuvant chemotherapy prior to hepatectomy remains controversial. Methods: We retrospectively analyzed 466 consecutive patients with resectable CRLM between 2000 and 2010. Patient and tumor characteristics, surgical procedure and survival data were recorded. Results: The patients were divided into two groups: one group with neoadjuvant chemotherapy (group NC, n=121) and one group without (group WN, n=345). There was no significant difference in the median survival (60.0 m vs. 53.9 m) or 5-year survival (52% vs. 48%) between the two groups. No significant differences were identified between the two groups in terms of 30-day mortality (1.7% vs. 1.2%) or morbidity (33.9% vs. 25.8%). A primary tumor at stage T4, ≥ 4 liver metastases, the largest liver metastasis ≥ 5 cm in diameter, and a serum CEA level ≥ 5 ng/ml were independent prognostic factors for the surgical patients. By assigning one point to each of above factors, all of the patients were divided into a low-risk group (0-2) and a high-risk (3-4). The patients in the low-risk group received no survival benefit from neoadjuvant chemotherapy, whereas those in the high-risk group received a survival benefit (median survival, 38.9 m vs. 28.4 m; 5-year survival, 39% vs. 33%, P=0.028). Conclusions: Preoperative neoadjuvant chemotherapy did not significantly increase mortality or complications. Not all resectable patients (only those with more than 2 independent risk factors) receive a survival benefit from neoadjuvant chemotherapy.

Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study

2021 ◽  
Author(s):  
C. Behrenbruch ◽  
S. Prabhakaran ◽  
D. Udayasiri D ◽  
M. Michael ◽  
F. Hollande ◽  
...  
Keyword(s):  
Cohort Study ◽  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Imaging Response

The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study

2007 ◽  
Vol 451 (5) ◽  
pp. 943-948 ◽  
Author(s):  
Mark M. Aloysius ◽  
Abed M. Zaitoun ◽  
Ian J. Beckingham ◽  
Keith R. Neal ◽  
Guruprasad P. Aithal ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Comparative Study ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Pathological Response ◽  
Response To Neoadjuvant Chemotherapy

OC-059 The impact of disease progression with neoadjuvant chemotherapy in patients undergoing resection of colorectal liver metastases

Gut ◽  
2015 ◽  
Vol 64 (Suppl 1) ◽  
pp. A30.1-A30
Author(s):  
FK Welsh ◽  
K Chandrakumaran ◽  
TG John ◽  
AB Cresswell ◽  
M Rees
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Disease Progression ◽  
Colorectal Liver Metastases ◽  
The Impact

scholarly journals Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases

2016 ◽  
Vol 24 (1) ◽  
pp. 236-243 ◽  
Author(s):  
Kerstin Wimmer ◽  
Christoph Schwarz ◽  
Carmen Szabo ◽  
Martin Bodingbauer ◽  
Dietmar Tamandl ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Risk Scores ◽  
Clinical Risk

scholarly journals P-103 The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study

2020 ◽  
Vol 31 ◽  
pp. S123
Author(s):  
F. Camarda ◽  
F. Ardito ◽  
M. Bensi ◽  
M. Vellone ◽  
B. Di Stefano ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prognostic Factor ◽  
Liver Metastases ◽  
Primary Tumor ◽  
Colorectal Liver Metastases ◽  
Tumor Site ◽  
Primary Tumor Site
Sign in / Sign up

Export Citation Format

Share Document